ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
A phase 1/2 trial of ProAgio Dose Levels (DL) 1,2,3,4 in triple-negative breast cancer, run by ProDa BioTech, LLC, now recruiting.
Overview
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer is a phase 1/2 interventional study registered as NCT06460298 by ProDa BioTech, LLC, with 51 participants planned, started 2024-08-20 and due to reach its primary completion in 2027-07-01. Interventions recorded: ProAgio Dose Levels (DL) 1,2,3,4 and ProAgio Dose Expansion.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialPersonalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialNuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialDual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialSKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.